These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 37318478

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
    Scoccianti G, Totti F, Scorianz M, Baldi G, Roselli G, Beltrami G, Franchi A, Capanna R, Campanacci DA.
    Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
    [Abstract] [Full Text] [Related]

  • 3. Combined preoperative denosumab and adjuvant microwave ablation for high-risk giant cell tumor of bone: a retrospective study in a single center.
    Zheng C, Xu G, Zhou X, Qiu J, Lan T, Zhang S, Li W.
    J Orthop Surg Res; 2024 Aug 17; 19(1):488. PubMed ID: 39154187
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?
    Hindiskere S, Errani C, Doddarangappa S, Ramaswamy V, Rai M, Chinder PS.
    Clin Orthop Relat Res; 2020 Nov 17; 478(11):2522-2533. PubMed ID: 32401001
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A, Tsuchiya H, Ishii T, Nishida Y, Abe S, Matsumine A, Kawai A, Yoshimura K, Ueda T.
    BMC Musculoskelet Disord; 2016 Jul 22; 17():306. PubMed ID: 27448567
    [Abstract] [Full Text] [Related]

  • 10. Mid-term outcome after curettage with polymethylmethacrylate for giant cell tumor around the knee: higher risk of radiographic osteoarthritis?
    van der Heijden L, van de Sande MA, Heineken AC, Fiocco M, Nelissen RG, Dijkstra PD.
    J Bone Joint Surg Am; 2013 Nov 06; 95(21):e159. PubMed ID: 24196471
    [Abstract] [Full Text] [Related]

  • 11. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ, Ma TX, Qi DW, Zhao M, Hu T, Zhang GC.
    Orthop Surg; 2019 Dec 06; 11(6):1101-1108. PubMed ID: 31762217
    [Abstract] [Full Text] [Related]

  • 12. Convolutional neural network to predict the local recurrence of giant cell tumor of bone after curettage based on pre-surgery magnetic resonance images.
    He Y, Guo J, Ding X, van Ooijen PMA, Zhang Y, Chen A, Oudkerk M, Xie X.
    Eur Radiol; 2019 Oct 06; 29(10):5441-5451. PubMed ID: 30859281
    [Abstract] [Full Text] [Related]

  • 13. A novel subchondral bone-grafting procedure for the treatment of giant-cell tumor around the knee: A retrospective study of 27 cases.
    Wu M, Yao S, Xie Y, Yan F, Deng Z, Lei J, Cai L.
    Medicine (Baltimore); 2018 Nov 06; 97(45):e13154. PubMed ID: 30407342
    [Abstract] [Full Text] [Related]

  • 14. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
    Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, Donati DM.
    J Bone Joint Surg Am; 2018 Mar 21; 100(6):496-504. PubMed ID: 29557866
    [Abstract] [Full Text] [Related]

  • 15. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
    Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, Roberts ZJ, Bach BA.
    Ann Surg Oncol; 2015 Sep 21; 22(9):2860-8. PubMed ID: 26033180
    [Abstract] [Full Text] [Related]

  • 16. Ultra-Short Course of Neo-Adjuvant Denosumab for Nerve-Sparing Surgery for Giant Cell Tumor of Bone in Sacrum.
    Liang H, Liu X, Yang Y, Guo W, Yang R, Tang X, Yan T, Li Y, Tang S, Li D, Qu H, Dong S, Ji T, Du Z, Zang J.
    Spine (Phila Pa 1976); 2022 May 01; 47(9):691-701. PubMed ID: 34961753
    [Abstract] [Full Text] [Related]

  • 17. Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery.
    Asano N, Saito M, Kobayashi E, Morii T, Kikuta K, Watanabe I, Anazawa U, Takeuchi K, Suzuki Y, Susa M, Nishimoto K, Ishii R, Miyazaki N, Mrioka H, Kawai A, Horiuchi K, Nakayama R.
    Ann Surg Oncol; 2022 Jun 01; 29(6):3992-4000. PubMed ID: 35175454
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.
    Chinder PS, Hindiskere S, Doddarangappa S, Pal U.
    Clin Orthop Surg; 2019 Sep 01; 11(3):352-360. PubMed ID: 31475058
    [Abstract] [Full Text] [Related]

  • 19. Denosumab for Bone Giant Cell Tumor of the Distal Radius.
    Tsukamoto S, Mavrogenis AF, Tanzi P, Leone G, Ciani G, Righi A, Akahane M, Honoki K, Tanaka Y, Donati DM, Errani C.
    Orthopedics; 2020 Sep 01; 43(5):284-291. PubMed ID: 32745221
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study.
    Urakawa H, Yonemoto T, Matsumoto S, Takagi T, Asanuma K, Watanuki M, Takemoto A, Naka N, Matsumoto Y, Kawai A, Kunisada T, Kubo T, Emori M, Hiraga H, Hatano H, Tsukushi S, Nishida Y, Akisue T, Morii T, Takahashi M, Nagano A, Yoshikawa H, Sato K, Kawano M, Hiraoka K, Tanaka K, Iwamoto Y, Ozaki T.
    World J Surg Oncol; 2018 Aug 08; 16(1):160. PubMed ID: 30089488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.